Catalent Expert to Chair Panel Discussion on Integrated Clinical Drug Development Partnerships at Upcoming Bio Supply Management Alliance Conference
SOMERSET, N.J. – March 2, 2023 — Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that its Vice President of Business Transformation and Regional General Manager, Matt Blume, will host a panel session at the upcoming Bio Supply Management Alliance (BSMA) Conference, to be held at the Crowne Plaza Suites Hotel, Foster City, California, on March 8 – 9, 2023.
The session, on Wednesday, March 8 at 4:15 p.m. PST, is entitled “The Industry Platform to Integrate Drug Developers with CRO, CMO, and CDMOs,” and will also include experts from SK Pharmteco, Vir Biotechnology, SAP and Avidity BioScience. The panel will discuss strategies that enable the collaboration of personnel and integration of organizations, as well as information in the drug development ecosystem that can reduce time to market, lower cost of development and improve launch times.
In his role at Catalent, Mr. Blume provides oversight of the company’s clinical supply sites across the U.S. West Coast, and is General Manager of its Kansas City, Missouri, facility. He has worked at the company for over 20 years and has led the transformation initiative of the clinical supply business by implementing enterprise resource planning (ERP) systems and global processes across sites. He holds a Bachelor of Science in Pharmacy from the University of Kansas.
With a network spanning the U.S., U.K., Germany, Singapore, Japan and China, plus more than 50 additional global depots, Catalent’s clinical supply services can handle a broad range of international compliance and distribution requirements to support global clinical trials.
To find out more information about this event, visit www.catalent.com/events/bsma-summit-2023/
NOTES FOR EDITORS
ABOUT CATALENT CLINICAL SUPPLY SERVICES
Catalent solves today’s clinical trial challenges and develops innovative solutions for the future. The company’s commitment to quality and service excellence is evident in its flexible solutions, modern global facilities, and over 25 years’ experience of reliably supplying thousands of studies of all sizes and complexities, all around the world.
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit